USPTO Examiner BAIG RUMAISA RASHID - Art Unit 3796

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19025992Circuit Module for Pelvic Floor Muscle Rehabilitation Device and Pelvic Floor Muscle Rehabilitation DeviceJanuary 2025December 2025Abandon1110NoNo
18665231SYSTEMS AND METHODS TO PROMOTE TISSUE HEALTH VIA ELECTRICAL STIMULATIONMay 2024November 2025Allow1830YesNo
18487190Composite Phonocardiogram Visualization on an Electronic Stethoscope DisplayOctober 2023July 2025Abandon2121YesNo
17899624OPTICAL DEVICEAugust 2022November 2025Abandon3810NoNo
17879731FLEXIBLE ULTRA-THIN LED SKIN PATCH AND MANUFACTURING METHOD THEREOFAugust 2022January 2026Allow4210NoNo
17850500ELECTROCARDIOGRAM ELECTRODE APPLICATION SYSTEMJune 2022February 2026Abandon4420NoNo
17833843HIGH VISUAL ACUITY, HIGH SENSITIVITY LIGHT SWITCHABLE NEURAL STIMULATOR ARRAY FOR IMPLANTABLE RETINAL PROSTHESISJune 2022May 2025Abandon3510NoNo
17780773HUMAN BODY SENSING MATMay 2022October 2025Abandon4110NoNo
17711009METHOD AND SYSTEM FOR MEDICAL DIAGNOSIS USING GRAPH EMBEDDINGSMarch 2022September 2025Abandon4230NoNo
17763452SLEEP STAGE ESTIMATION DEVICE, SLEEP STAGE ESTIMATION METHOD AND PROGRAMMarch 2022July 2025Abandon4020YesNo
17656034METHOD FOR TREATING SLEEP DISORDER BASED ON DATA AND APPARATUS FOR PERFORMING THE METHODMarch 2022August 2025Abandon4120YesNo
17656156APPARATUSES, SYSTEMS AND METHODS FOR IMPLANTABLE STIMULATOR WITH EXTERNALLY TRAINED CLASSIFIERMarch 2022December 2025Abandon4521NoNo
17650495Closed Loop Control in Spinal Cord StimulationFebruary 2022January 2026Allow4740YesYes
17571509PORTABLE UROFLOWMETRY APPARATUS, UROFLOWMETRY AND CREATING MICTURITION CHART SYSTEM USING THE SAME, AND UROFLOWMETRY METHODJanuary 2022March 2025Abandon3801NoNo
17619561System for the Treatment of Disorders Associated with InflammationDecember 2021August 2024Abandon3210NoNo
17611519FACIAL BEAUTY DEVICE AND MASK SHEET USED THEREFORNovember 2021September 2025Abandon4620NoNo
17522924ADDRESSABLE ELECTRODE ARRAY SYSTEMS, DEVICES AND METHODSNovember 2021December 2024Abandon3720NoNo
17448630METHODS AND SYSTEMS FOR TREATMENT OF FEEDING DISORDERSSeptember 2021December 2024Abandon3910NoNo
17439779RAPID NEURAL RESPONSE TELEMETRY CIRCUIT AND SYSTEM OF COCHLEAR IMPLANTSeptember 2021January 2025Abandon4020NoNo
17387413COMPOSITE PHONOCARDIOGRAM VISUALIZATION ON AN ELECTRONIC STETHOSCOPE DISPLAYJuly 2021November 2025Abandon5131YesNo
17370250SYSTEMS AND METHODS FOR LABELING DATA IN ACTIVE IMPLANTABLE MEDICAL DEVICE SYSTEMSJuly 2021May 2025Abandon4730YesNo
17331061METHOD FOR DETERMINING A POSITION OF A LASER FOCUS OF A LASER BEAM OF AN EYE SURGICAL LASER, AS WELL AS TREATMENT APPARATUSMay 2021November 2024Allow4220YesNo
17293616BENDING MECHANISM AND MEDICAL EQUIPMENTMay 2021June 2024Allow3710NoNo
17319169DIAGNOSTICS FOR DETECTION OF ISCHEMIC HEART DISEASEMay 2021July 2025Abandon5030YesYes
17292472WEARABLE APPARATUS AND METHOD FOR MONITORING MEDICAL PROPERTIESMay 2021June 2024Abandon3710NoNo
17227510MEDICAL POWER TOOLApril 2021March 2024Abandon3510NoNo
17228139OPTICAL SENSOR DEVICEApril 2021December 2025Allow5731YesNo
17210609RATCHETING HANDLE FOR MEDICAL INSTRUMENTMarch 2021March 2024Allow3501YesNo
17268192DEVICES AND METHODS FOR PERCUTANEOUS ELECTRODE IMPLANTFebruary 2021April 2024Allow3801NoNo
17266798METHOD AND SYSTEM FOR ASSESSING EMERGENCY RISK FOR PATIENTSFebruary 2021July 2024Abandon4110NoNo
17260267INDWELLING HYPER-DIMENSIONAL CARDIAC PHYSIOLOGIC DATA LOGGING AND TRANSMISSION SYSTEM AND METHOD OF DOING BUSINESSJanuary 2021May 2024Abandon4010NoNo
17143026WIRE GRIPPING DEVICEJanuary 2021July 2024Allow4311YesNo
17114467USER INTERFACE FOR A SURGICAL ROBOTIC SYSTEMDecember 2020January 2026Abandon6031NoNo
17051027SURGICAL ROBOT SYSTEMOctober 2020December 2024Abandon5010NoNo
17015199Universal tool adapterSeptember 2020December 2024Allow5121YesNo
16931554MODULAR ROBOTIC SURGICAL SYSTEMSJuly 2020December 2025Abandon6041YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BAIG, RUMAISA RASHID.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
11.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BAIG, RUMAISA RASHID - Prosecution Strategy Guide

Executive Summary

Examiner BAIG, RUMAISA RASHID works in Art Unit 3796 and has examined 22 patent applications in our dataset. With an allowance rate of 31.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner BAIG, RUMAISA RASHID's allowance rate of 31.8% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BAIG, RUMAISA RASHID receive 1.73 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BAIG, RUMAISA RASHID is 42 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +40.2% benefit to allowance rate for applications examined by BAIG, RUMAISA RASHID. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 4% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 23% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 7% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.